Dragonfly Therapeutics startet Phase 1/1b-Studie seiner IL-2-Immuntherapie bei Patient:innen mit fortgeschrittenen soliden Tumoren ...Middle East

Das Unternehmen gibt den/die erste behandelte(n) Patient:in in einer klinischen Studie der Phase 1/1b bekannt, in der das neuartige IL-2-Zytokins DF6215 untersucht wird – das siebte von Dragonfly entwickelte Medikament, das in klinische Studien eingetreten ist. WALTHAM, Massachusetts, 6....

Hence then, the article about dragonfly therapeutics startet phase 1 1b studie seiner il 2 immuntherapie bei patient innen mit fortgeschrittenen soliden tumoren was published today ( Wednesday 06/12/2023 - 03:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Dragonfly Therapeutics startet Phase 1/1b-Studie seiner IL-2-Immuntherapie bei Patient:innen mit fortgeschrittenen soliden Tumoren )

Also on site :

• Who Is Anthony Kazmierczak? Ilhan Omar Attack Suspect Identified
• Bobby Bones Is Barely Recognizable After Rescuing a Stranger During Winter Storm Fern
• 2000s Heavy Metal Band Aims for ‘Suspended Illusion’ on Its 20th Anniversary Tour